Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program
Mind Exchange Working Group… - Clinical Infectious …, 2013 - academic.oup.com
Many practical clinical questions regarding the management of human immunodeficiency
virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to …
virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to …
Clinical significance of human immunodeficiency virus type 1 replication fitness
C Dykes, LM Demeter - Clinical microbiology reviews, 2007 - Am Soc Microbiol
The relative fitness of a variant, according to population genetics theory, is that variant's
relative contribution to successive generations. Most drug-resistant human …
relative contribution to successive generations. Most drug-resistant human …
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels
JJ Parienti, M Das-Douglas, V Massari, D Guzman… - PloS one, 2008 - journals.plos.org
Background While the relationship between average adherence to HIV potent antiretroviral
therapy is well defined, the relationship between patterns of adherence within adherence …
therapy is well defined, the relationship between patterns of adherence within adherence …
Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates
J Stover, R Glaubius, R Kassanjee… - Journal of the …, 2021 - Wiley Online Library
Abstract Introduction The Spectrum/AIM model is used by national HIV programs and
UNAIDS to prepare annual estimates of key HIV indicators. This article describes key …
UNAIDS to prepare annual estimates of key HIV indicators. This article describes key …
A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption
SD Allard, B De Keersmaecker, AL de Goede… - Clinical …, 2012 - Elsevier
In a phase I/IIa clinical trial, 17 HIV-1 infected patients, stable on cART, received 4
vaccinations with autologous dendritic cells electroporated with mRNA encoding Tat, Rev …
vaccinations with autologous dendritic cells electroporated with mRNA encoding Tat, Rev …
A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption
VM Andrade, C Mavian, D Babic… - Proceedings of the …, 2020 - National Acad Sciences
HIV-1 persists in cellular reservoirs that can reignite viremia if antiretroviral therapy (ART) is
interrupted. Therefore, insight into the nature of those reservoirs may be revealed from the …
interrupted. Therefore, insight into the nature of those reservoirs may be revealed from the …
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy
JH Willig, S Abroms, AO Westfall, J Routman… - Aids, 2008 - journals.lww.com
Methods: Retrospective study of antiretroviral-naive patients starting treatment at the
University of Alabama at Birmingham 1917 HIV/AIDS Clinic 1 January 2000–31 July 2007 …
University of Alabama at Birmingham 1917 HIV/AIDS Clinic 1 January 2000–31 July 2007 …
Clinical trials of antiretroviral treatment interruption in HIV-infected individuals
Despite the benefits of antiretroviral therapy (ART) for people living with HIV, there has been
a long-standing research interest in interrupting ART as a strategy to minimize adverse …
a long-standing research interest in interrupting ART as a strategy to minimize adverse …
Standing genetic variation and the evolution of drug resistance in HIV
PS Pennings - PLoS computational biology, 2012 - journals.plos.org
Drug resistance remains a major problem for the treatment of HIV. Resistance can occur due
to mutations that were present before treatment starts or due to mutations that occur during …
to mutations that were present before treatment starts or due to mutations that occur during …
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)
B Autran, RL Murphy, D Costagliola, R Tubiana… - Aids, 2008 - journals.lww.com
Objective: Evaluate immunogenicity and clinical efficacy of two immunization strategies with
the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients …
the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients …